30.15
price down icon0.89%   -0.27
after-market Handel nachbörslich: 30.15
loading
Schlusskurs vom Vortag:
$30.42
Offen:
$30.23
24-Stunden-Volumen:
669.84K
Relative Volume:
0.67
Marktkapitalisierung:
$2.77B
Einnahmen:
$4.72M
Nettoeinkommen (Verlust:
$-277.91M
KGV:
-8.0831
EPS:
-3.73
Netto-Cashflow:
$-203.56M
1W Leistung:
+1.24%
1M Leistung:
-12.41%
6M Leistung:
-48.64%
1J Leistung:
-29.83%
1-Tages-Spanne:
Value
$29.97
$31.43
1-Wochen-Bereich:
Value
$28.75
$31.43
52-Wochen-Spanne:
Value
$24.10
$62.53

Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile

Name
Firmenname
Crinetics Pharmaceuticals Inc
Name
Telefon
858-450-6464
Name
Adresse
10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA
Name
Mitarbeiter
437
Name
Twitter
@Crinetics
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
CRNX's Discussions on Twitter

Vergleichen Sie CRNX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CRNX
Crinetics Pharmaceuticals Inc
30.15 2.77B 4.72M -277.91M -203.56M -3.73
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-25 Eingeleitet Stifel Buy
2025-02-11 Eingeleitet TD Cowen Buy
2025-02-04 Eingeleitet Wolfe Research Peer Perform
2025-01-22 Hochstufung Jefferies Hold → Buy
2024-03-06 Eingeleitet Citigroup Buy
2024-01-16 Eingeleitet Morgan Stanley Overweight
2023-12-21 Eingeleitet Jefferies Hold
2023-11-20 Fortgesetzt JP Morgan Overweight
2023-10-24 Fortgesetzt Cantor Fitzgerald Overweight
2023-08-31 Eingeleitet Oppenheimer Outperform
2023-04-24 Eingeleitet Piper Sandler Overweight
2023-03-30 Eingeleitet Robert W. Baird Outperform
2021-11-30 Eingeleitet JMP Securities Mkt Outperform
2021-11-23 Eingeleitet Evercore ISI Outperform
2021-06-18 Hochstufung JP Morgan Neutral → Overweight
2019-12-23 Eingeleitet ROTH Capital Buy
2019-02-14 Eingeleitet H.C. Wainwright Buy
2018-08-13 Eingeleitet JP Morgan Neutral
2018-08-13 Eingeleitet Leerink Partners Outperform
2018-08-13 Eingeleitet Piper Jaffray Overweight
Alle ansehen

Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten

pulisher
09:33 AM

Wells Fargo & Company MN Increases Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

09:33 AM
pulisher
04:13 AM

Invesco Ltd. Acquires 42,954 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

04:13 AM
pulisher
Apr 20, 2025

Russell Investments Group Ltd. Sells 43,501 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Apr 20, 2025
pulisher
Apr 17, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Acquired by Affinity Asset Advisors LLC - MarketBeat

Apr 17, 2025
pulisher
Apr 14, 2025

Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Unloaded Rep. Josh Gottheimer - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by Alliancebernstein L.P. - Defense World

Apr 13, 2025
pulisher
Apr 13, 2025

JPMorgan Chase & Co. Has $13.78 Million Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Apr 13, 2025
pulisher
Apr 13, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 | CRNX Stock News - GuruFocus

Apr 12, 2025
pulisher
Apr 11, 2025

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 - The Manila Times

Apr 11, 2025
pulisher
Apr 11, 2025

Key Investor Alert: Crinetics Sets Date for Crucial Q1 2025 Financial Results - Stock Titan

Apr 11, 2025
pulisher
Apr 10, 2025

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com

Apr 10, 2025
pulisher
Apr 10, 2025

Acromegaly Pipeline 2025: Detailed Clinical Trials - openPR.com

Apr 10, 2025
pulisher
Apr 10, 2025

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 10, 2025
pulisher
Apr 10, 2025

Growth Signal: Crinetics Awards Major Equity Package in Latest Hiring Wave - Stock Titan

Apr 10, 2025
pulisher
Apr 05, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Sei Investments Co. - Defense World

Apr 05, 2025
pulisher
Apr 02, 2025

Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA - Seeking Alpha

Apr 02, 2025
pulisher
Mar 31, 2025

CRNX stock touches 52-week low at $31.81 amid market challenges - Investing.com

Mar 31, 2025
pulisher
Mar 27, 2025

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation Of Marketing Authorization Application (MAA) And Orphan Drug Designation (ODD) For Paltusotine In Acromegaly - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

Breakthrough: First Oral Acromegaly Drug Hits Major EU Milestone with Dual Regulatory Wins - Stock Titan

Mar 27, 2025
pulisher
Mar 26, 2025

Crinetics Pharmaceuticals (NASDAQ:CRNX) Now Covered by Stifel Nicolaus - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology - Benzinga

Mar 25, 2025
pulisher
Mar 25, 2025

This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

Mar 25, 2025
pulisher
Mar 25, 2025

Stifel Initiates Coverage of Crinetics Pharmaceuticals (CRNX) with Buy Recommendation - Nasdaq

Mar 25, 2025
pulisher
Mar 25, 2025

Stifel Initiates Crinetics Pharmaceuticals at Buy With $60 Price Target - Marketscreener.com

Mar 25, 2025
pulisher
Mar 24, 2025

Cushing's Syndrome Pipeline 2025: Therapies, MOA Insights, - openPR.com

Mar 24, 2025
pulisher
Mar 24, 2025

(CRNX) Trading Report - news.stocktradersdaily.com

Mar 24, 2025
pulisher
Mar 24, 2025

Connor Clark & Lunn Investment Management Ltd. Sells 13,735 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Mar 24, 2025
pulisher
Mar 23, 2025

Proficio Capital Partners LLC Purchases Shares of 14,674 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Mar 23, 2025
pulisher
Mar 22, 2025

Crinetics Pharmaceuticals COO Jeff Knight sells $244,963 in stock By Investing.com - Investing.com Australia

Mar 22, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals’ chief med and dev officer sells $86,020 in stock - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Stock: Executives Sell Shares Amid Analyst Optimism - sharewise.com

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals’ chief med and dev officer sells $86,020 in stock By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals CEO Richard Struthers sells shares worth $592,016 By Investing.com - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals COO Jeff Knight sells $244,963 in stock - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals chief scientific officer sells $197,352 in stock By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals CEO Richard Struthers sells shares worth $592,016 - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals chief scientific officer sells $197,352 in stock - Investing.com

Mar 21, 2025
pulisher
Mar 19, 2025

CRNX News Today | Why did Crinetics Pharmaceuticals stock go down today? - MarketBeat

Mar 19, 2025
pulisher
Mar 19, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Mar 19, 2025
pulisher
Mar 16, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Charles Schwab Investment Management Inc. - Defense World

Mar 16, 2025
pulisher
Mar 14, 2025

US Bancorp DE Sells 5,176 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Where are the Opportunities in (CRNX) - Stock Traders Daily

Mar 13, 2025
pulisher
Mar 13, 2025

Will Crinetics Pharma's Upcoming Events Drive Stock Momentum? - RTTNews

Mar 13, 2025
pulisher
Mar 12, 2025

Bank of New York Mellon Corp Has $17.63 Million Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Mar 12, 2025
pulisher
Mar 10, 2025

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Crinetics Pharmaceuticals Grants Stock Options and RSUs to New Employees Under 2021 Inducement Plan - Nasdaq

Mar 10, 2025

Finanzdaten der Crinetics Pharmaceuticals Inc-Aktie (CRNX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Kapitalisierung:     |  Volumen (24h):